Supportive Oligonucleotide Technique in Carmel, IN
Supportive Oligonucleotide Technique, SOT, is a technique in which circulating tumor cells are reverse-engineered using a messenger RNA to disrupt the DNA of the cancer cell in order to destroy them. Each SOT treatment is custom-made for each individual’s cancer cells. It is highly specific to only affect the cancer cells. The messenger RNA target is usually the most upregulated apoptosis gene found within the tumor. Apoptosis is a process of programmed cell death that occurs in multicellular organisms. Apoptosis plays a critical role in normal biological processes requiring cell removal including differentiation, development, and homeostasis. Insufficient amounts of apoptosis results in uncontrolled cell proliferation, such as cancer. In cancer, the apoptosis cell-division ratio is altered allowing the cancer cells to have “immortality.”
SOT has the ability to induce apoptosis (cell death) in circulating cancer tumors, stem cells, all primary and metastatic tumors regardless of size and is able to cross the blood-brain barrier. SOT will remain active in the bloodstream for approximately 24-28 weeks since SOT truly has a stealth characteristic (meaning it is unnoticed by the body’s RNase). SOT will work 24/7 and has no decreased efficacy with any concurrent cancer treatments except rarely chemotherapy and/or radiation.
SOT will be administered by a simple 30-minute I.V. The patient is given an I.V. injection right before the SOT to ensure proper efficacy. There hasn’t been any known anaphylactic reactions from this procedure. Occasionally an individual will complain of a mild headache or fever or flu life symptoms due to the “die off” from terminating cancer cells. Caution must be used with patients whom have a large number of tumors and/or a large tumor size or that have tumors that are located in organs where apoptosis (cell death induced edema) is occurring because this may have a negative impact on vital function. In these cases, it is best to split the SOT into smaller doses and increase the duration between each injection.
In 1978, Paul Zamecnik and Mary Stephenson reported the first experiments on antisense mechanisms of gene silencing using short synthetic antisense oligonucleotides to inhibit replication of a rales sarcoma virus by binding and blocking the action of 35s RNA. In the following years, attention turned to the possible therapeutic applications of antisense technology. Since that time, six antisense treatments have been approved by the FDA.